BrainStorm

Company Overview

Snapshot

Founded in January 2000, BrainStorm operates with 11–50 employees and has raised a total of $67.13M across 17 funding rounds from 3 investors. The company went public on NASDAQ in October 2003, marking a significant milestone in its journey to develop autologous stem cell therapeutics.

Business overview

BrainStorm Cell Therapeutics is a pioneering company focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's core technology, NurOwn®, involves transforming autologous mesenchymal stem cells into neurotrophic factor-secreting cells to deliver critical growth factors to affected areas. BrainStorm operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers, patients, and the biotechnology and pharmaceutical industries in markets like Japan and the United States.

Strategic signal

In October 2024, BrainStorm Cell Therapeutics announced presentations on NurOwn® at the 2024 Annual NEALS Meeting and presented positive survival data from its NurOwn® Expanded Access Program. This indicates ongoing clinical development and efforts to demonstrate the efficacy of its lead therapeutic candidate, signaling continued commitment to advancing treatments for neurodegenerative diseases despite prior regulatory challenges.

Company Intelligence Q&A

What is BrainStorm Cell Therapeutics' primary therapeutic product?

BrainStorm Cell Therapeutics' primary therapeutic product is NurOwn®, which utilizes autologous mesenchymal stem cells to treat neurodegenerative disorders like ALS and MS.

When did BrainStorm Cell Therapeutics go public?

BrainStorm Cell Therapeutics went public on NASDAQ in October 2003.

What was a significant recent regulatory development for NurOwn®?

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment prioritizing NurOwn® for the treatment of ALS and planned to meet with the US FDA to discuss its development plan, following an advisory panel vote against recommending approval earlier that month.

Has BrainStorm Cell Therapeutics received any grants for its research?

In November 2019, BrainStorm Cell Therapeutics announced a research grant award from the National Multiple Sclerosis Society. In April 2020, the company was awarded a grant from the Israel Innovation Authority.

What recent financial update did BrainStorm Cell Therapeutics provide?

The company also announced its Third Quarter 2025 Financial Results and Corporate Update in November 2025.